CTLA4-Ig treatment prolongs rat orthotopic liver graft survival.
Tu
Y
Y
Department of Surgery, Washington University School of Medicine, St Louis, Missouri 63110, USA.
Rehman
A
A
Flye
M W
MW
D000069594:Abatacept; D000818:Animals; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000627:therapeutic use*; D001663:Bilirubin / Q000097:blood; D060908:CTLA-4 Antigen; D006085:Graft Survival / Q000276:immunology*; D006801:Humans; D018796:Immunoconjugates; D007165:Immunosuppression Therapy / Q000379:methods; D016031:Liver Transplantation / Q000276:immunology* / Q000502:physiology; D008297:Male; D051381:Rats; D011917:Rats, Inbred Lew; D011919:Rats, Inbred Strains; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D013997:Time Factors; D014184:Transplantation, Homologous
D015703:Antigens, CD; D000943:Antigens, Differentiation; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; C556708:Ctla4 protein, rat; D018796:Immunoconjugates; D011994:Recombinant Proteins; D000069594:Abatacept; D001663:Bilirubin